02/20/19
The NASDAQ 100 Pre Market Indicator is down 2 09 to 7 064 52 The total Pre Market volume is currently 4 121 282 shares traded The following are the most active stocks for the pre market session New Residential Investment Corp NRZ is 0 54 at 16 48 with 2 205
02/19/19
In the past year Merck amp Co Inc MRK has been one of the biggest gainers along with Eli Lilly LLY 160 Merck s stock has risen 45 2 in the past year compared with a 7 4 increase for the industry Merck s performance in 2018 was supported by strong quarterly results
02/19/19
Global spending on cancer drugs has soared in recent years along with the number of expensive new treatments reaching patients in need of new options Roche NASDAQOTH RHHBY led the industry with around 26 billion in oncology sales last year but losses from aging brands will
02/19/19
The NASDAQ 100 Pre Market Indicator is down 14 08 to 7 041 1 The total Pre Market volume is currently 5 355 331 shares traded The following are the most active stocks for the pre market session ArcelorMittal MT is 0 68 at 22 40 with 1 109 133 shares traded
02/15/19
AstraZeneca PLC AZN was a big mover last session as the company saw its shares rise more than 9 on the day The move came on solid volume too with far more shares changing hands than in a normal session This breaks the recent trend of the company as the stock is now trading above the
02/14/19
Thursday was a volatile day on Wall Street as major stock indexes lost a lot of ground early in the day but then rebounded to finished mixed Gains for the Nasdaq Composite came even as Dow Jones Industrial Average 160 fell modestly and although investors spent much of
02/14/19
InvestorPlace Stock Market News Stock Advice amp Trading Tips AstraZeneca earnings for the fourth quarter of 2018 has AZN stock heading higher on Thursday Source Shutterstock AstraZeneca NYSE AZN reported earnings per share of 1 58 for the fourth quarter of the
02/14/19
Ironwood Pharmaceuticals Inc IRWD incurred fourth quarter 2018 adjusted loss of 2 cents per share narrower than the Zacks Consensus Estimate of a loss of 17 cents as well as the loss of 14 cents in the year ago period Total revenues in the fourth quarter were 130 7 million reflecting
02/14/19
In trading on Thursday shares of AstraZeneca plc Symbol AZN crossed above their 200 day moving average of 37 69 changing hands as high as 39 76 per share AstraZeneca plc shares are currently trading up about 8 4 on the day The chart below shows the one year performance of AZN
02/14/19
Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Bristol Myers Squibb BMY and Astrazeneca AZN But which of these two stocks is more attractive to value investors We ll need to take a closer look to find out There are plenty of strategies
02/14/19
AstraZeneca plc AZN beat the Zacks Consensus Estimate for both earnings and sales in the fourth quarter of 2018 Pascal Soriot AstraZeneca s chief executive officer said AstraZeneca has returned to growth as its product sales grew for two consecutive quarters Per Soriot 2019 will be
02/13/19
What happened After reporting fourth quarter financial results that were better than expected on both the top and bottom line and updating investors on its plans to split into two companies Ironwood Pharmaceuticals NASDAQ IRWD surged 11 7 higher today So
02/13/19
The following companies are expected to repor t earnings prior to market open on 02 14 2019 Visit our Earnings Calendar for a full list of expected earnings releases Coca Cola Company KO is reporting for the quarter ending December 31 2018 The
02/06/19
AstraZeneca: Fasenra Gets FDA's ODD For Hypereosinophilic Syndrome - Quick Facts
02/06/19
AstraZeneca: Fasenra Gets FDA's ODD For Hypereosinophilic Syndrome - Quick Facts
02/05/19
AstraZeneca: RSV Medicine MEDI8897 Gets FDA's BTD, EMA's PRIME Eligibility
02/05/19
AstraZeneca: RSV Medicine MEDI8897 Gets FDA's BTD, EMA's PRIME Eligibility
02/04/19
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its nex t quarterly report Astrazeneca AZN which belongs to the Zacks Large Cap Pharmaceuticals industry could be a great candidate to consider
02/04/19
Alkermes Plc ALKS announced that the FDA has issued a Complete Response Letter CRL related to its new drug application NDA for ALKS 5461 The NDA sought approval for the candidate as an adjunctive treatment of major depressive disorder MDD The regulatory authority refused
01/25/19
AstraZeneca Announces Completion Of Divestment Of US Rights To Synagis
01/25/19
AstraZeneca Announces Completion Of Divestment Of US Rights To Synagis
AZN - Astrazeneca PLC